What is Senisca?
SENISCA is an award-winning biotechnology company originating from the University of Exeter. The company's core mission is to modulate RNA biology to combat age-related diseases. SENISCA's innovative approach centers on targeting the process of cellular aging, also known as senescence, through the development of RNA senotherapeutics. These novel therapeutics are designed to specifically address the underlying molecular mechanisms that drive senescence, offering a potential new avenue for treating age-related conditions.
How much funding has Senisca raised?
Senisca has raised a total of $7.2M across 2 funding rounds:
Angel/Seed
$2.5M
Other Financing Round
$4.7M
Angel/Seed (2022): $2.5M with participation from Longevity Tech Fund, Emerging Longevity Ventures, R42 Fund, and Trend Ventures
Other Financing Round (2024): $4.7M led by APEX Ventures and R42 Group
Key Investors in Senisca
Longevity Tech Fund
Longevity Tech Fund is an investment firm focused on the burgeoning field of longevity and rejuvenation biotechnology, likely backing companies with innovative scientific approaches to extending human healthspan.
Emerging Longevity Ventures
Emerging Longevity Ventures is an investment firm focused on rejuvenation biotechnology. They invest in early-stage companies and often take a lead-investor role, providing follow-on financing. The company seeks out promising scientific advancements in the field of longevity.
APEX Ventures
APEX Ventures is a venture capital firm focused on deep-tech and medical innovations, aiming to build the next generation of world-leading companies. The firm is run by founders with complementary backgrounds and a shared mission to support startups with disruptive technology.
What's next for Senisca?
With the recent major strategic investment, Senisca is poised for significant advancement in its quest to develop RNA senotherapeutics. The company's focus on cellular aging and its underlying molecular drivers positions it at the forefront of longevity research. This latest backing is anticipated to fuel further research and development, potentially leading to clinical trials and the eventual commercialization of its innovative treatments. Senisca's trajectory suggests a strong emphasis on scientific validation and strategic partnerships to bring its therapeutic solutions to market.
See full Senisca company page
